• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Bicycle Therapeutics

    Bicycle Therapeutics Provides Data Updates for Three Clinical Programs and Strategy Overview at First R&D Day
    From Bicycle Therapeutics
    Via Business Wire
    Tickers BCYC
    Bicycle Therapeutics to Host R&D Day on December 14
    From Bicycle Therapeutics
    Via Business Wire
    Tickers BCYC
    Bicycle Therapeutics Selected to Participate in FDA Program to Expedite Commercial Manufacturing Readiness of BT8009 for Metastatic Bladder Cancer
    From Bicycle Therapeutics
    Via Business Wire
    Tickers BCYC
    Bicycle Therapeutics Announces Expedited Development Plan for BT8009 in Metastatic Bladder Cancer
    From Bicycle Therapeutics
    Via Business Wire
    Tickers BCYC
    Bicycle Therapeutics to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
    From Bicycle Therapeutics
    Via Business Wire
    Tickers BCYC
    Bicycle Therapeutics to Participate in Upcoming Investor Conferences
    From Bicycle Therapeutics
    Via Business Wire
    Tickers BCYC
    Bicycle Therapeutics Announces Phase I Dose Escalation Results from Ongoing Phase I/II Study of BT8009
    From Bicycle Therapeutics
    Via Business Wire
    Tickers BCYC
    Bicycle Therapeutics to Present Five Posters Highlighting Preclinical Data from its Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) Programs at the SITC 37th Annual Meeting
    From Bicycle Therapeutics
    Via Business Wire
    Tickers BCYC
    Bicycle Therapeutics Announces First Patient Dosed in BT8009 Phase II Expansion Cohorts and Provides Program Update
    From Bicycle Therapeutics
    Via Business Wire
    Tickers BCYC
    Bicycle Therapeutics to Participate in the Jefferies Healthcare Conference
    From Bicycle Therapeutics
    Via Business Wire
    Tickers BCYC
    Bicycle Therapeutics to Present Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting
    From Bicycle Therapeutics
    Via Business Wire
    Tickers BCYC
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.